BREAKING
BioAge Labs 2025 Financial Results Analysis 46 minutes ago Heidmar Maritime Holdings Corp. (HMR) Q4 Earnings: Misses on EPS, Revenue Recap 1 hour ago Hour Loop, Inc. (HOUR) Reports FY2025 Results 2 hours ago Heidmar Maritime Holdings Corp. (HMR) Misses Q4 EPS Estimates 2 hours ago Sanara MedTech Inc. (SMTI) Q4 Earnings: Misses on EPS, Revenue Recap 3 hours ago LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected 3 hours ago UTStarcom Holdings Corp. (UTSI) Reports Q2 Earnings 3 hours ago Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates 3 hours ago LightInTheBox Holding Co., Ltd. (LITB) Q4 2025 Earnings Recap 3 hours ago LightInTheBox Holding Co., Ltd. (LITB) Reports Q4 Earnings 3 hours ago BioAge Labs 2025 Financial Results Analysis 46 minutes ago Heidmar Maritime Holdings Corp. (HMR) Q4 Earnings: Misses on EPS, Revenue Recap 1 hour ago Hour Loop, Inc. (HOUR) Reports FY2025 Results 2 hours ago Heidmar Maritime Holdings Corp. (HMR) Misses Q4 EPS Estimates 2 hours ago Sanara MedTech Inc. (SMTI) Q4 Earnings: Misses on EPS, Revenue Recap 3 hours ago LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected 3 hours ago UTStarcom Holdings Corp. (UTSI) Reports Q2 Earnings 3 hours ago Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates 3 hours ago LightInTheBox Holding Co., Ltd. (LITB) Q4 2025 Earnings Recap 3 hours ago LightInTheBox Holding Co., Ltd. (LITB) Reports Q4 Earnings 3 hours ago
ADVERTISEMENT
Breaking News

Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9%

Sanara MedTech Inc.

March 24, 2026 2 min read

Sanara MedTech Inc.

SMTISMTI|EPS -$0.13 vs $0.11 est (-215.9%)|Rev $27.5M|Net Loss $1.1M

Sanara MedTech Inc. reported a surprise loss for the fourth quarter of 2025, with GAAP earnings coming in at -$0.13 per share against analyst expectations of a $0.11 profit. The medical technology company, which markets surgical and wound care products to healthcare providers, missed the consensus estimate by 215.9%. The bottom line showed a net loss of $1.1M for the period.

Revenue totaled $27.5M for the quarter, representing 5.0% year-over-year growth. The company’s soft tissue repair products segment continued to drive performance, generating $24.7M in revenue with a 5.0% year-over-year increase. These products remain the cornerstone of Sanara’s portfolio as it serves physicians, hospitals, clinics, and post-acute care settings.

For the full year ahead, management set revenue guidance at $116.0M to $121.0M. The forecast comes as the company navigates a competitive landscape in the wound care and surgical products market, balancing growth initiatives against profitability challenges that emerged in the latest quarter.

A detailed analysis of Sanara MedTech Inc.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT